Use the hyperlinks, where available to access additional clinical trial information.
An Open-label, Multicenter, Non-randomized, Dose Escalation Phase 1 Trial to Evaluate Safety and Tolerability of SHR-1210 in Patients With Advanced Solid Tumors
Atridia Pty Ltd.
This is an open-label, multicenter, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 in patients with advanced solid tumors. The trial will enroll patients with advanced solid tumor who have failed current standard anti-tumor therapies.